Share Your Vape With Your Pals? We've Got Grim News
No judgement from us, but if you've been partial to a cheeky puff from a friend's vape – or even offer your own up – after a few drinks, now may be the time to stop sharing.
This is because, amid a cocktail of winter illnesses doing the rounds, doctors have warned of a 'quad-demic' with levels of flu, Covid-19, respiratory syncytial virus and norovirus increasing, according to Dr Hana Patel who is an NHS GP.
With this in mind, the experts at Electric Tobacconist have collaborated with Dr Patel to outline the potential health risks of sharing a vape and also how best to clean your vape to prevent infections.
Norovirus is a serious infection that is found in poo or vomit and can be very easily transmitted to food, water, and surfaces by the hands of infected people.
Anybody who has had norovirus will tell you that this illness is VERY hard-going.
While sharing a vape is not a common way to contract norovirus, touching or using a vape that has been used by someone with the virus increases the risk.
Dr Patel explains: 'I would not recommend sharing vapes as this can expose you to a number of diseases and viruses, especially with rising cases of norovirus.'
Vaping involves inhaling aerosol, and this can contain drops of saliva.
With this in mind, it's no surprise that sharing a vape can increase the risks of transmitting respiratory infections such as cold and flu, as well as Covid-19 and pneumonia.
In order to limit your chances of catching a viral infection during the colder months, it's very important to avoid sharing a vape, even with close friends.
As lovely as it is to share a vape after several pints, it does increase your risk of catching glandular fever, too. Other things that are great after a few drinks including kissing, sharing glasses and sharing utensils – and all of these can also spread the disease. Booo.
Dr Patel urges: 'Not only can sharing a vape increase the risk of contracting viral infections, but it can also increase the risk of contracting herpes.
'While herpes is known as a sexually transmitted disease, it can also be spread through non-sexual contact through sharing personal items, such as a vape. If you experience any symptoms such as sores, pain, or blisters, it's important to seek a doctor's advice for a diagnosis.'
Dr Patel adds: 'Sharing with friends may also mean you are getting higher doses of nicotine than you're used to. If you choose to vape, I would recommend keeping yourself healthy and safe by using your own personalised vape and keeping it clean with proper maintenance to reduce these risks.'
Pascal Culverhouse, a spokesperson from Electric Tobacconist, recommends regularly rinsing the tank and mouthpiece of your vape with warm water to prevent bacterial buildup. For deeper cleans, use mild soap.
'For disposable vapes, store them in a cool, dry place and avoid extreme temperatures to maintain performance,' he added. 'Regularly clean the mouthpiece with a cloth or alcohol wipe and avoid sharing to prevent the spread of germs.'
Love Vaping? This Doctor Has A Warning For Your Tongue
Vaping May Not Be The Healthy Alternative To Smoking That We Thought It Was
Quitting Smoking For New Years? This Surgeon Has News About A Popular Method
Stop Smoking Pill: What We Know So Far About The New NHS Treatment
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Younger women could have cervical screening every five years instead of three
Younger women who test negative for the virus that causes most cases of cervical cancer will be recalled for NHS screening every five years rather than three. The changes mean that, from next month, women aged 25 to 49 in England who are negative for human papillomavirus (HPV) will receive screening invites every five years. The move has been recommended by the UK National Screening Committee and is based on analysis from King's College London showing five-yearly screening is just as safe as three-yearly, with the same number of cancers found. HPV is a sexually-transmitted group of viruses which cause no symptoms. Around 13 high-risk types of HPV are known to cause 99.7% of all cervical cancers. As at present, any woman who has HPV or has a recent history of HPV will continue to be invited to more frequent screenings to check the virus has cleared and, if not, to check for cell changes in the cervix. In a written statement to Parliament, health minister Ashley Dalton said the new change 'increases the opportunities to test and recall women and people with a cervix who have HPV, while extending the cervical screening intervals from three to five years in England for individuals who have a negative HPV test. 'This will bring England's cervical screening intervals in line with those of Wales and Scotland.' She said the NHS screening programme in England provides all women between the ages of 25 and 64 'with the opportunity to be screened routinely to detect HPV infection or cervical abnormalities at an early, more treatable stage'. She added: 'The aim of the programme is to reduce the number of women who develop invasive cervical cancer and reduce the number who die from it.' Ms Dalton said testing negative for HPV means the chances of developing cancer within five years are very small, as it can take around 10 years or more from the time HPV is detected to developing cervical cancer. She added: 'Those who test positive for HPV are already being followed up with yearly testing. 'This is important to ensure that individuals are monitored for any early signs of cervical abnormalities and provided the necessary treatment.' Experts have been concerned about falling numbers of women under 50 attending cervical screening, with around a third in England not taking up their invitations. Dr Sue Mann, NHS national clinical director for women's health, said: 'Taking a more personalised approach to cervical screening will help ensure everyone eligible can make the most of these life-saving services, while sparing women appointments that they don't need. 'The NHS is following robust evidence on how often women need to be safely screened, and by putting invitations and reminders straight in women's pockets on their phones, we're making it easier than ever to take up screening appointments. 'Make sure you come forward for your screening when you're invited, even if it was weeks, months or years ago. If you think you are due but have not yet had an invitation, speak to your GP practice.' Michelle Mitchell, chief executive of Cancer Research UK, said: 'We welcome this change to cervical screening in England, which is the result of years of vital research to make screening more effective and has shown it is safe to extend the time between tests. 'Screening, alongside the roll out of the HPV vaccine – which Cancer Research UK scientists helped develop – have seen cervical cancer rates drop by around a quarter since the early 1990s, and we look forward to even more progress. 'If you notice any unusual changes for you, do not wait for a screening invitation – speak to your doctor.' Athena Lamnisos, chief executive of the Eve Appeal, said: 'We want every eligible person to feel empowered to attend a vaccination and cervical screening appointment when they are invited so we can achieve the brilliant ambition of eliminating cervical cancer.'
Scientific American
17 minutes ago
- Scientific American
Can You Still Get a COVID Vaccine This Fall? Here's What to Know
For the first time since the COVID vaccines became available in pharmacies in 2021, the average person in the U.S. can't count on getting a free annual shot against a disease that has been the main or a contributing cause of death for more than 1.2 million people around the country, including nearly 12,000 to date this year. 'COVID's not done with us,' says Jennifer Nuzzo, an epidemiologist at Brown University. 'We have to keep using the tools that we have. It's not like we get to forget about COVID.' In recent weeks, the Department of Health and Human Services, led by prominent antivaccine activist Robert F. Kennedy, Jr., has announced a barrage of measures that are likely to reduce COVID vaccine access, leading to a swirl of confusion about what will be available for the 2025–2026 season. HHS officials did not respond to a request for comment for this article. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Government officials appear to be limiting COVID shots to people who are aged 65 and older and to those who have certain preexisting health conditions—groups that have long been known to face a higher risk of developing severe COVID. Pregnant people and some children, meanwhile, appear to be explicitly excluded from access, despite plentiful evidence that vaccines are very safe and effective for them and that COVID infections can cause them significant harm. Scientific American spoke with clinicians and public health experts about the latest COVID vaccine recommendations, what access may look like this fall and how these policies might influence people's vaccination choices and health. What COVID vaccines will be manufactured this year? Public health experts are monitoring a strain of the COVID-causing virus SARS-CoV-2 called NB.1.8.1, which was first detected early this year and last month became responsible for one in 10 COVID cases globally. So far, the new variant has mostly been reported in Asia and Europe. But it has also been picked up in airport surveillance in multiple U.S. states, says Peter Chin-Hong, an infectious disease physician and a professor of medicine at the University of California, San Francisco. The emergence of a new variant isn't surprising, particularly at this time of year, Chin-Hong says. 'It's kind of acting like clockwork—maybe this might be the variant of the summer,' he adds. Still, NB.1.8.1 has led to concerns about a potential surge in cases—although Chin-Hong and other scientists don't have any evidence so far that it causes more serious disease than other currently circulating strains. 'All of these new variants, they might be more transmissible, they might be more immune evasive, but I've seen no data whatsoever that suggests that they're more pathogenic,' says Angela Rasmussen, a virologist at the University of Saskatchewan. Within the U.S., a strain called LP.8.1 has been the most common one detected since March. Both NB.1.8.1 and LP.8.1 are among the alphabet soup of strains that descended from a key ancestor lineage called Omicron JN.1, which dominated U.S. cases by early 2024. Current vaccines target this category of strains. And in May a Food and Drug Administration panel determined that, this year, vaccine producers should again tailor their shots to a single strain within the JN.1 lineage—preferably LP.8.1. What's going on with COVID vaccine policy? Strain selection aside, the recent messaging and decision-making on vaccine policy for COVID and beyond have been chaotic, with various governmental groups and officials announcing different access guidelines and restrictions. 'The situation we're in right now is nuts,' says Nuzzo, referring to the fact that agency leaders have sidestepped the formal science committees that traditionally make vaccine-related decisions. 'We don't change vaccine policy on a willy-nilly basis. There's an incredible amount of nuance, and all of the data need to be considered.' But on June 9 Kennedy took a major step against this evidence-driven decision-making process by firing the entire CDC Advisory Committee on Immunization Practices (ACIP). Kennedy announced the committee rehaul in a Wall Street Journal op-ed, in which he alleged there were 'persistent conflicts of interest' among committee members. According to a recent HHS statement, new committee members are under consideration, and the group will still meet as scheduled from June 25 to 27. ACIP has traditionally been particularly important because any vaccine it recommends must be fully paid for by health insurance companies—a condition that greatly determines real-world access. It's unclear what the committee's overhaul will mean for COVID vaccine access in particular. Another concern is that Kennedy announced in late April that HHS would implement a policy requiring all 'new' vaccines—including updated versions of existing ones, such as COVID shots—to be tested against a placebo. The original COVID vaccines were tested in just this manner. But conducting similar tests when an effective and very safe vaccine already exists would be not only unethical for researchers but also expensive and time-consuming for manufacturers. It remains unclear when the new policy will take effect. What does this mean for COVID vaccine access this fall? If you are 65 years old or older, you should be able to get a COVID shot as you have in recent years. If you have an underlying condition such as cancer, diabetes, or heart or lung problems, you may also be able to get a COVID shot as usual. These issues and several others are on the CDC's list of conditions that leave people more vulnerable to severe disease, and this list is included in the description of the new regulatory framework. One 2021 study looked at many (but not all) of the conditions on the list and estimated that three in four U.S. adults has at least one. People are allowed to self-disclose a preexisting condition at pharmacies without a prescription or doctor's note. That list could also be expanded later if new research finds other risk factors that increase people's risk of severe COVID, says Jacinda Abdul-Mutakabbir, a clinical pharmacist and an assistant professor at the University of California, San Diego. But there's also a chance that qualifying conditions may be reduced instead. For example, current or recent pregnancy is included in the CDC's existing list, but HHS officials announced in late May that the COVID vaccine would no longer be recommended for pregnant people. Data have shown that COVID may cause various complications during pregnancy —increasing the risk that the pregnant person may require emergency care, be put on a ventilator or die. The newborn child of an infected person is also more likely to be born preterm or to have low birth weight. And babies younger than six months old—who are ineligible for vaccination because of their immature immune system—have the highest rates COVID hospitalization after adults aged 75 and older. In contrast, evidence from people vaccinated during pregnancy show that newborns receive protective immunity through antibodies that cross the placenta and are found in breast milk, Chin-Hong explains. Healthy children also face new restrictions to COVID vaccine access: The shot is now only recommended to them based on 'shared clinical decision-making,' according to the vaccine schedules released by the CDC last month. This means parents must consult with a health practitioner about whether to vaccinate such children. Experts worry about the consequences of restricting access for kids. Children under age 18 make up a smaller percentage of COVID hospitalizations and deaths. But that doesn't mean zero risk, Chin-Hong says. 'We know that COVID still kills kids,' he says. 'No death of a child is a good death—and these are all preventable.' 'Because children and pregnant people are considered vulnerable populations, they were not included in the original studies that were done for the COVID vaccines,' Abdul-Mutakabbir says. But five years' worth of real-world vaccine data from these groups show the health benefits. 'We do see effectiveness and safety in these vaccines,' she says. It's still possible that the late June ACIP meeting will shift the landscape again. But if you want a COVID vaccine this fall and don't meet current guidelines, you may still be able to request a shot. Your insurance may not pay for it, however, leaving you to risk a price tag of around $200. 'Insurance companies or providers are only required to pay for vaccines that are listed as recommended by the CDC,' Abdul-Mutakabbir says. Full, partial or no-cost coverage for nonrecommended vaccines is at the insurance provider's discretion. Any changes to coverage—and the times at which those changes are announced—will vary among programs, including private and governmental ones, such as the federal-state program Medicaid and the federal program Medicare. Until then, Chin-Hong and Abdul-Mutakabbir say, the COVID vaccines released in the fall of 2024 are still recommended and available to people who haven't already had one. And as of April 26, only 23 percent of adults and 13 percent of children in the U.S. had received the shot. 'If you are nervous about the surge or planning summer travel, I would recommend' getting the vaccine, Abdul-Mutakabbir says. The larger fight over vaccines For Rasmussen, the confusion over COVID shots signals the beginning of a longer tug-of-war—with Kennedy's HHS on one end. 'I think I know what their plan is, and it's to reduce access to vaccines in general,' she says. 'In my view, this is an incremental step in a larger attack on vaccination in general.' She encourages people worried about vaccine restrictions—and about the role of science in making these decisions—to call their congressional legislators. 'A lot of people speaking out is what is needed right now to make a big difference here,' she says. Abdul-Mutakabbir also hopes people continue to seek vaccines for COVID and other diseases—especially while they are still easily available. 'It's important that we consider the things that we can protect ourselves against,' Abdul-Mutakabbir says. 'Should you have a barrier with getting a COVID vaccine, guess what? There's no change to the flu vaccine; there's no changes to the pneumococcal recommendations; there's no change to measles, mumps, rubella vaccine. Get the vaccines that we can get.'
New York Times
30 minutes ago
- New York Times
F.D.A. Looks to A.I. to Enhance Efficiency
The Food and Drug Administration is planning to use artificial intelligence to 'radically increase efficiency' in deciding whether to approve new drugs and devices, one of several top priorities laid out in an article published Tuesday in JAMA. Another initiative involves a review of chemicals and other 'concerning ingredients' that appear in U.S. food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count. 'The F.D.A. will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children and common-sense approaches to rebuild the public trust,' Dr. Marty Makary, the agency commissioner, and Dr. Vinay Prasad, who leads the division that oversees vaccines and gene therapy, wrote in the JAMA article. The agency plays a central role in pursuing the agenda of the U.S. health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that artificial intelligence is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. 'I don't want to be dismissive of speeding reviews at the F.D.A.,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' Want all of The Times? Subscribe.
